Wacker Chemie AG: directors' dealings · Germany · BaFin

About Wacker Chemie AG

Wacker Chemie AG is a German specialty chemicals and biotechnology group listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany. For French-, Belgian- and Swiss-based investors, the company represents a long-established industrial compounder with deep roots in Bavaria and a current headquarters in Munich. Founded in 1914, Wacker has evolved from a historically broad chemical business into a more focused global platform centered on silicones, polymers, biosolutions and polysilicon, with an emphasis on high-value applications, technical know-how and integrated manufacturing. The group operates through four core business divisions. Silicones is Wacker’s largest franchise and supplies a broad portfolio used across construction, mobility, electronics, healthcare, consumer goods and industrial applications. Polymers develops binders and polymer additives, especially dispersible polymer powders and polymer dispersions, which are widely used in adhesives, coatings and building materials. Biosolutions combines customized biotechnology solutions and catalog products for fine chemicals, with an increasing focus on biopharma and functional ingredients. Polysilicon produces hyperpure polysilicon for the semiconductor and solar industries. In its latest reporting, Wacker described itself as a global leader in building-protection silicones, the world’s largest producer of VAE dispersions and dispersible polymer powders, and one of the leading global suppliers of hyperpure polysilicon. A key part of Wacker’s competitive positioning is its industrial integration. The company highlights highly integrated material loops at its major production sites, especially Burghausen, Nünchritz and Zhangjiagang, which support efficiency, scale and process reliability. The group also benefits from a diversified international footprint spanning Europe, Asia and the Americas. In 2024, Wacker reported sales distribution of roughly 39% in Europe, 37% in Asia and 18% in the Americas, underscoring its global reach and balance across end markets. Recent milestones indicate a company still investing in capability-building despite a challenging market backdrop. In 2024 Wacker opened its new headquarters in Munich’s Werksviertel district, reinforcing its German base and modernizing its corporate infrastructure. In 2025, it opened a Biotechnology Center in Munich to accelerate research in biopharmaceutical manufacturing and nutrition-related ingredients. The silicones division has continued capacity expansion, including projects in China and Europe, while the polysilicon business has remained focused on adding semiconductor-grade capacity at Burghausen. For equity investors, Wacker Chemie combines exposure to specialty materials, industrial cyclicality and secular growth themes such as electrification, healthcare, advanced manufacturing and semiconductors.